(RTTNews) - Pasithea Therapeutics Corp. (KTTA) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PAS-004 to treat neurofibromatosis type 1 (NF1)-associated cutaneous neurofibromas (cNF).